Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
January 19, 2016
CSEQ-SIMULATOR: A DATA SIMULATOR FOR CLIP-SEQ EXPERIMENTS
Wanja Kassuhn, Uwe Ohler, Philipp Drewe
Cancers
|
June 28, 2023
In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
Wanja Kassuhn, Pedro R Cutillas, Mirjana Kessler, et al.
Cancers
|
July 26, 2020
Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging
Hagen Kulbe, Oliver Klein, Zhiyang Wu, et al.
Cancers
|
April 3, 2021
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
Wanja Kassuhn, Oliver Klein, Silvia Darb-Esfahani, et al.
Gynecologic Oncology
|
June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer
Carlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
January 19, 2016
CSEQ-SIMULATOR: A DATA SIMULATOR FOR CLIP-SEQ EXPERIMENTS
Wanja Kassuhn, Uwe Ohler, Philipp Drewe
Cancers
|
June 28, 2023
In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
Wanja Kassuhn, Pedro R Cutillas, Mirjana Kessler, et al.
Cancers
|
July 26, 2020
Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging
Hagen Kulbe, Oliver Klein, Zhiyang Wu, et al.
Cancers
|
April 3, 2021
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
Wanja Kassuhn, Oliver Klein, Silvia Darb-Esfahani, et al.
Gynecologic Oncology
|
June 23, 2022
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer
Carlotta Keunecke, Hagen Kulbe, Felix Dreher, et al.
Page
of 1